Malignant tumors of the testis: Analysis of treatment results and sites and causes of failure

Quivey, Jeanne M.; Fu, Karen K.; Herzog, Karen A.; Weiss, Jerome M.; Phillips, Theodore L.

doi:10.1002/1097-0142(197703)39:3<1247::aid-cncr2820390334>3.0.co;2-e

Cited by 36 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These tumors typically metastasize to the lung and supraclavicular or mediastinal lymph nodes (31). Clinically apparent metastases to the cervical (supraclavicular) nodes occur in : 22% of patients (31 -33).…”

Section: Testicular Carcinomamentioning

confidence: 99%

Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinoma: A Diagnostic and Therapeutic Challenge

Ferlito¹,

Shaha²,

Buckley³

et al. 2001

Acta Oto-Laryngologica

View full text Add to dashboard Cite

Section: Testicular Carcinomamentioning

confidence: 99%

Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinoma: A Diagnostic and Therapeutic Challenge

Ferlito¹,

Shaha²,

Buckley³

et al. 2001

Acta Oto-Laryngologica

View full text Add to dashboard Cite

“…l!tl\Vever, data reported by Tyrell, 89 Castro,9 \{ac Kay.,. .Vhitmore, 100 and Quivey 61 show that almo-.t all rl'currences are due to distant spread either by lymphatic and/or hematogenous dissemination.…”

Section: Ln-ln+ 24mentioning

confidence: 99%

Testicular Cancer: Risk Factors and the Role of Adjuvant Chemotherapy

Jacobs

1980

Cancer

View full text Add to dashboard Cite

Advances in therapeutic results due to chemotherapy in metastatic non-seminomatous germinal cell tumors of the testes are stimulating investigations that assess the role of chemotherapy as an adjuvant to surgery and/or radiotherapy in early stages of disease. In current series, complete responses are obtained in 70-80% of patients with metastatic disease; the relapse rate is 15-20%. Toxicity is significant but acceptable. The current literature reveals that surgery and/or radiation to the periaortic lymph nodes for clinical Stage I disease results in a 2+ year disease-free survival rate of about 90%. For clinical Stage II disease, the rate is about 50%. Patients with non-seminomatous testicular carcinoma Stage II are at significant risk to develop distant metastases and are candidates for an intergroup protocol that randomizes patients to receive either adjuvant combination chemotherapy or combination chemotherapy at first recurrence. All patients with testicular cancer should be considered curable. This requires careful assessment and monitoring, and can best be approached in controlled clinical trials.

show abstract

Radiation therapy for germinal tumors of the testes

Slawson

1978

Cancer

View full text Add to dashboard Cite

79 patients with germinal tumors of the testes were treated at the University of Maryland Radiation Therapy Clinic between January 1, 1957 and December 31, 1973. 32 of 33 patients with stage I seminoma had disease controlled for a minimum of three years for a 96.9% 3 year disease‐free determinant survival. 4 of 4 patients with stage I carcinoma were treated, two after negative node dissection, and all survived. 15 of 21 patients with stage II seminoma survived for 3 year disease‐free Berkson‐Gage actuarial survival of 68.5%. 9 of 21 stage II carcinomas, 18 of whom had had positive node dissections, survived for a 3 year disease‐free Berkson‐Gage actuarial survival of 42.8%. Benefit of adjuvant irradiation of the mediastinum and supraclavicular regions is demonstrated for stage II seminomas where 7/8 patients receiving prophylaxis demonstrated a 100% 3 year disease‐free Berkson‐Gage actuarial survival as opposed to the 50.4% in the 7/13 patients surviving without adjuvant therapy. This benefit is reaffirmed, although more tenuously, by the 71.4% 3 year disease‐free Berkson‐Gage actuarial survival demonstrated by the 5 of 7 stage II carcinoma patients receiving adjuvant therapy as opposed to the 28.2% demonstrated by the 4 of 14 patients surviving who did not receive adjuvant therapy. Cancer 42:2216–2223, 1978.

show abstract

Malignant tumors of the testis: Analysis of treatment results and sites and causes of failure

Cited by 36 publications

References 14 publications

Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinoma: A Diagnostic and Therapeutic Challenge

Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinoma: A Diagnostic and Therapeutic Challenge

Testicular Cancer: Risk Factors and the Role of Adjuvant Chemotherapy

Radiation therapy for germinal tumors of the testes

Contact Info

Product

Resources

About